Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 MillionGlobeNewsWire • 10/20/26
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 10/02/26
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 09/08/26
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/26
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. WainwrightMarketBeat • 07/22/26
Surrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/26
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?Zacks Investment Research • 04/14/26
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 03/23/26
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/25
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/25
Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a TurnaroundZacks Investment Research • 05/16/25
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayGlobeNewsWire • 05/14/25
Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/25
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesGlobeNewsWire • 03/31/25
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye DiseasesGlobeNewsWire • 03/24/25
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FibrosisGlobeNewsWire • 11/04/24